Mr Daniell is a member of the Council of the University of Auckland, a director of Cochlear Limited, Tait Limited and the Medical Research Commercialisation Fund, and Chair of the Medical Technologies Centre of Research Excellence. He is a member of Risk Committee.

Mr Gradon during his 37-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.

Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is non-executive director of Sonic Healthcare, Osprey Medical and Q'Biotics Group, a member of the Australian Board of Taxation, and a director of the South East Sydney Local Health District Board. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission. He is a member of Quality, Safety and Regulatory Committee.

Dr McIntyre has knowledge in health and technology - with experience in strategy, finance, technology transformation and data analytics. Dr McIntyre is an experienced company director with a portfolio that spans the health care, insurance, technology and e-learning sectors. She is currently a non-executive director of Insurance and Care NSW (a government public financial corporation), HCF Group (a private health insurance company in Australia), The University of Sydney, Studiosity and Nanosonics, and chair of LEK Consulting's ANZ Advisory Board. Prior to her director roles, Dr McIntyre spent 20 years as a senior strategy partner with LEK Consulting. She helped develop the company's US biotechnology advisory practice from three clients in the emerging sector to become the largest biotechnology practice in the US, providing strategic, commercial and operational advice to local and multinational companies in North America, Asia and Australia. She will also serve as a member of the Quality, Safety and Regulatory Committee, effective 1 October 2021 of FPH.

Mr O'Dwyer is a director of Cochlear Limited, Mesoblast Limited and nib Holdings Limited. From 1996 to 2003, he was with Cordis Cardiology, initially as its president (Europe) and from 2000 to 2003 as its worldwide president. He worked for 12 years with Baxter Healthcare, as a plant manager in Ireland & then president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is the chairman of Quality, Safety & Regulatory Committee and member of People Committee.

Ms McBride has been in the technology industry for 30 years and has global experience. She has held senior executive roles at SAP AG and Dell Inc, and is a former President of SAP North America. She is a director of National Australia Bank and Sky Network Television Ltd, and the founder and CEO of MyWave.

Mr Carter was managing director of Foodstuffs New Zealand Limited for ten years until his retirement in 2010. He is chairman of the board of TR Group and Datacom Group, a director of Vector Limited and ANZ Bank New Zealand Limited, and a trustee of the Maurice Carter Charitable Trust. He is a member of Quality, Safety & Regulatory, People and Risk Committee.

Ms Greenwood is a director of Spark New Zealand Limited, Westpac New Zealand Limited and a2 Milk Company Limited, a current trustee of the Auckland Writers Festival and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. She was a partner at Russell McVeagh between 2001 and 2019 and previously served as the firm's Board Chair. She has advised on market transactions. She is the chairman of People Committee.

-

-